Skip to main content

Table 5 Molecular docking results of available proteins and drugs

From: Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization

Target

PDB ID

Drug

PubChem ID

Binding energy (kcal/mol)

TGFB1

5VQP

butyric acid

264

-4.17

TGFB1

5VQP

clofibrate

2796

-5.9

TGFB1

5VQP

Sorafenib

216,239

-5.32

TGFB1

5VQP

Andrographolide

5,318,517

-4.93

TGFB3

8V52

butyric acid

264

-4.4

EP300

8GZC

butyric acid

264

-3.3

TP53

6MY0

butyric acid

264

-4.05

CDK4

2W96

clofibrate

2796

-5.74

CDK4

2W96

Sorafenib

216,239

-5.65

CDK4

2W96

Andrographolide

5,318,517

-7.11

HMGCR

1HW9

clofibrate

2796

-4.35

TP53

6MY0

clofibrate

2796

-5.05

TP53

6MY0

Sorafenib

216,239

-7.05

TP53

6MY0

Andrographolide

5,318,517

-6.05

  1. The lower the Binding energy, the better the binding effect and the higher the affinity